Inclusion Criteria:

          1. Signed and dated IEC-approved Informed Consent

          2. Diagnosis of sinonasal tumor with the following histotypes:

               -  Squamous Cell Carcinoma (SCC);

               -  Sinonasal Undifferentiated Carcinoma (SNUC);

               -  Small Cell Carcinoma Neuroendocrine Type (SmCCNET);

               -  Pure Sinonasal Neuroendocrine Carcinoma (SNEC);

               -  Intestinal Type Adenocarcinoma (ITAC) with a functional p53 gene;

               -  Esthesioneuroblastoma with differentiation grade III-IV by Hyams The inclusion of
                  the maxillary sinus carcinomas is reserved only in cases requiring exenteratio
                  orbitae for a radical surgery.

          3. AJCC stage II-III-IVa with the exception of Esthesioneuroblastoma and Intestinal Type
             Ethmoid Adenocarcinoma where stage III-IV only will be included.

          4. Resectable disease.

          5. ECOG performance status 0-2.

          6. Adequate bone marrow, renal and hepatic functionality, defined as haemoglobin >10
             g/dL, neutrophils >1500/mmc, platelets > 100.000/mmc, creatinine value ≤ 1.5 x ULN or
             calculated creatinine clearance (by Cockcroft and Gault's formula) > 60 mL/min,
             transaminases values < 1.5 times over the upper normal limit (ULN).

          7. Polychemotherapy treatment clinical feasibility as per Investigator's Judgment.

          8. Male or female patients ≥ 18 years of age.

          9. Negative pregnancy test (if female in reproductive years).

         10. Agreement upon the use of effective contraceptive methods (hormonal or barrier method
             of birth control, or abstinence) prior to study entry and for the duration of study
             participation, if men and women of child producing potential.

        Exclusion Criteria:

          1. Previous radiotherapy or chemotherapy for head and neck district tumors (surgical
             treatment relapses are admitted).

          2. Metastatic disease.

          3. Cardiac, pulmonary, infective, neurological disease or any other medical condition
             that could interfere with treatment.

          4. Unable and unwilling to comply with scheduled visits, therapy plans, and laboratory
             tests required in this protocol.

          5. Previous diagnosis of other malignant neoplasm in the last 3 years (in situ cervical
             cancer or completely excised basocellular/squamocellular skin cancer are always
             admitted).

          6. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or may
             interfere with the interpretation of study results and, in the judgment of the
             Investigator, would make the patient inappropriate for entry into this study or could
             compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

          7. Current or concomitant enrollment in another therapeutic clinical trial.